RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
        • 주제분류
        • 발행연도
        • 작성언어
        • 저자
          펼치기

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies

        Ohashi Takashi,Fujita Yukiyoshi,Irisawa Hiroyuki,Nakaminami Hidemasa,Arai Takahiro,Takahashi Masumi,Momiyama Emi,Murata Naoya,Murayama Kayoko,Saito Taeko 대한감염학회 2022 Infection and Chemotherapy Vol.54 No.1

        Background Arbekacin (ABK) is an aminoglycoside that exhibits anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-Pseudomonas aeruginosa activities. Therefore, for patients with febrile neutropenia (FN) and concurrent pneumonia suspected to be caused by MRSA, ABK may be sufficiently effective even as a single agent. Materials and Methods Patients with hematologic malignancies treated with ABK who met the following criteria were included: 1) fever during neutropenia or functional neutropenia, 2) FN complicated by pneumonia, and 3) possible infection by antimicrobial-resistant Gram-positive cocci. Results This study encompassed 22 episodes involving 19 patients, of which, 15 (68.2%) were successfully treated with ABK. Of the nine episodes showing inadequate response to other anti-MRSA drugs, eight were successfully treated with ABK. Grade 2 or worse adverse events included acute kidney injury (13.6%) and increased transaminase levels (9.1%). Conclusion The present study demonstrated that ABK is effective and safe in patients with FN and concurrent pneumonia caused by antimicrobial-resistant Gram-positive cocci. ABK may also be effective in patients who are unresponsive to other anti-MRSA drugs. Therefore, ABK may be beneficial in the treatment of pneumonia caused by antimicrobial-resistant Gram-positive cocci in patients with FN. Background Arbekacin (ABK) is an aminoglycoside that exhibits anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-Pseudomonas aeruginosa activities. Therefore, for patients with febrile neutropenia (FN) and concurrent pneumonia suspected to be caused by MRSA, ABK may be sufficiently effective even as a single agent. Materials and Methods Patients with hematologic malignancies treated with ABK who met the following criteria were included: 1) fever during neutropenia or functional neutropenia, 2) FN complicated by pneumonia, and 3) possible infection by antimicrobial-resistant Gram-positive cocci. Results This study encompassed 22 episodes involving 19 patients, of which, 15 (68.2%) were successfully treated with ABK. Of the nine episodes showing inadequate response to other anti-MRSA drugs, eight were successfully treated with ABK. Grade 2 or worse adverse events included acute kidney injury (13.6%) and increased transaminase levels (9.1%). Conclusion The present study demonstrated that ABK is effective and safe in patients with FN and concurrent pneumonia caused by antimicrobial-resistant Gram-positive cocci. ABK may also be effective in patients who are unresponsive to other anti-MRSA drugs. Therefore, ABK may be beneficial in the treatment of pneumonia caused by antimicrobial-resistant Gram-positive cocci in patients with FN.

      • SCIESCOPUSKCI등재

        ERRATUM : 'LYMANα EMITTERS BEYOND REDSHIFT 5: THE DAWN OF GALAXY FORMATION' (JKAS, 36, 123, [2003])

        Taniguchi, Yoshiaki,Shioya, Yasuhiro,Ajiki, Masaru,Fujita, Shinobu S.,Nagao, Tohru,Murayama, Takashi The Korean Astronomical Society 2003 Journal of The Korean Astronomical Society Vol.36 No.4

        The first sentence in the second paragraph of INTRODUCTION, 'The first discovery of a galaxy beyond z=5 was reported by Weymann et al. (1998); HDF 4-470.3 at z=5.60.' should be read as 'The first discovery of a galaxy beyond z=5 was reported by Dey et al. (1998); 0140+326 RD1 at z=5.34'. The authors sincerely regret this error.

      • SCIESCOPUSKCI등재

        LYMANα EMITTERS BEYOND REDSHIFT 5: THE DAWN OF GALAXY FORMATION

        TANIGUCHI YOSHIAKI,SHIOYA YASUHIRO,AJIKI MASARU,FUJITA SHINOBU S.,NAGAO TOHRU,MURAYAMA TAKASHI The Korean Astronomical Society 2003 Journal of The Korean Astronomical Society Vol.36 No.3

        The 8m class telescopes in the ground-based optical astronomy together with help from the ultra-sharp eye of the Hubble Space Telescope have enabled us to observe forming galaxies beyond red shift z = 5. In particular, more than twenty Ly$\alpha$-emitting galaxies have already been found at z > 5. These findings provide us with useful hints to investigate how galaxies formed and then evolved in the early universe. Further, detailed analysis of Ly$\alpha$ emission line profiles are useful in exploring the nature of the intergalactic medium because the trailing edge of cosmic reionization could be close to z $\~$ 6 -7, at which forming galaxies have been found recently. We also discuss the importance of superwinds from forming galaxies at high redshift, which has an intimate relationship between galaxies and the intergalactic medium. We then give a review of early cosmic star formation history based on recent progress in searching for Ly$\alpha$-emitting young galaxies beyond red shift 5.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼